The expression of CT83 was related to poor survival in non‐small‐cell lung cancer (NSCLC).12, 31 In a study of triple‐negative breast cancer, the expression rate of CT83 was reported to be as high as 75%, which is related to lymph node metastasis, lymphatic invasion, and disease stage.13 In our study, we found that the expression rate of CT83 was as high as 62.5% and 90.2% in colorectal cancer and nasopharyngeal carcinoma (unpublished data), respectively. Here, CT83 is linked to non-small cell lung carcinoma.